盘点:关于细胞自噬重磅研究精华汇总

2016-10-03 MedSci MedSci原创

就在今天10月3日“2016年诺贝尔生理或医学奖”得主为日本科学家大隅良典(Yoshinori Ohsumi),他的研究推动了对自噬的分子生物学机制以及自噬的生理功能的认识。大隅良典,1945年2月9日生,日本分子细胞生物学家。现任综合研究大学院大学名誉教授、基础生物学研究所名誉教授、东京工业大学前沿研究机构特聘教授。大隅教授是细胞自噬研究的先驱,曾获得京都奖、盖尔德纳国际奖及日本人第2座威利

就在今天10月3日“2016年诺贝尔生理或医学奖”得主为日本科学家大隅良典(Yoshinori Ohsumi),他的研究推动了对自噬的分子生物学机制以及自噬的生理功能的认识。

大隅良典,1945年2月9日生,日本分子细胞生物学家。现任综合研究大学院大学名誉教授、基础生物学研究所名誉教授、东京工业大学前沿研究机构特聘教授。大隅教授是细胞自噬研究的先驱,曾获得京都奖、盖尔德纳国际奖及日本人第2座威利奖。

自噬(autophagy)是由 Ashford 和 Porter 在 1962 年发现细胞内有“自己吃自己”的现象后提出的,是指从粗面内质网的无核糖体附着区脱落的双层膜包裹部分胞质和细胞内需降解的细胞器、蛋白质等成分形成自噬体(autophagosome),并与溶酶体融合形成自噬溶酶体,降解其所包裹的内容物,以实现细胞本身的代谢需要和某些细胞器的更新。

梅斯医学小编为大家汇总了那些关于细胞自噬重磅研究,一起学习进步,下一个诺贝尔奖说不定就是你!

【1】JCEM:雌激素诱导甲状腺乳头状癌细胞的自噬

甲状腺乳头状癌(PTC)的发生率在性别中的比例是女:男(1:3),关于性别差异的风险因素知之甚少。越来越多的研究认为雌激素在甲状腺肿瘤的发生中起重要作用,但是相关的机制并不清楚。近来有研究发现雌激素受体α(ER-α)可通过刺激活性氧的生成和胞外信号调节激酶诱导PTC的自噬。

研究者分析了ER-α在PTC患者甲状腺组织中的表达。通过化学和基因技术抑制PTC细胞自噬,检测PTC细胞的活力、增殖和凋亡情况。对PTC细胞系BCPAP中的ER-α和自噬水平都进行了检测。

结果显示,与邻近的非肿瘤组织相比,ER-α的表达在PTC组织中升高了。雌激素以一种ER-α依赖的方式诱导PTC细胞自噬。通过ER/ ER-α诱导的自噬与活性氧的生成、细胞外信号调节激酶(ERK1/2)以及PTC细胞的存活/增长比例相关。化学性或基因敲出技术抑制自噬可以显著的抑制肿瘤细胞存活,并且促进其凋亡,进一步明确自噬在PTC进展中的积极作用。

最后,研究者认为ER-α可以通过提高PTC细胞自噬水平,促进PTC细胞生长。抑制PTC细胞自噬,可能成为一种治疗ER-α阳性的PTC新方法。(文章详见--JCEM:雌激素诱导甲状腺乳头状癌细胞的自噬

【2】Oral Oncol:天然成分紫檀芪(Pterostilbene)可诱导口腔癌细胞自噬

紫檀芪(Pterostilbene)是一种天然的植物抗毒素,已在某些植物如葡萄叶,蓝莓和蔓越莓等中发现。紫檀芪具有多种药理活性,包括抗氧化活性和癌症预防活性,并能抑制DNA的合成。体外实验已经证明,紫檀芪对多种癌细胞(包括乳腺癌结肠癌,肝癌,皮肤癌和胃癌的细胞)具有细胞毒性。虽然紫檀芪可抑制多种癌细胞的增殖,并促进这些癌细胞的凋亡,但其促使癌细胞自噬的具体机制却尚未明了。本研究的目的是为了明确紫檀芪对口腔癌细胞自噬作用的独特影响。

研究结果显示,紫檀芪能够有效地抑制口腔癌细胞的生长,抑制细胞周期进行,促进细胞凋亡。此外,酸性自噬泡以及 LC3-II的产生还说明了紫檀芪具有诱导癌细胞自噬的作用。使用3-甲基苯丙胺(3-MA)以及巴弗洛霉素A1(BafA1)不同程度上可提高紫檀芪诱导口腔癌细胞凋亡的作用。紫檀芪诱导的癌细胞自噬作用是通过激活JNK1/2和抑制Akt, ERK1/2和 p38来引发的。

总之,该研究首次论证了紫檀芪可抑制癌细胞的生长,并可通过抑制Akt, ERK1/2和 p38诱导SAS和OECM-1细胞自噬,还可激活JNK1/2通道。自噬发生在紫檀芪诱导细胞凋亡的早期阶段。同时,我们还观察到,紫檀芪诱导的细胞自噬在SAA癌细胞及 OECM-1癌细胞中机制不同。(文章详见--Oral Oncol:天然成分紫檀芪(Pterostilbene)可诱导口腔癌细胞自噬

【3】Nat Commun:华人研究,自噬调节心肌梗死新模式

近日,来自青岛大学的研究人员在国际学术期刊nature communication在线发表了他们的最新研究进展,他们发现一种叫做自噬促进因子(APF)的长非编码RNA能够通过靶向miR-188-3p和ATG7调节自噬,在心肌梗死诊断和治疗方面具有一定意义。

研究人员发现miR-188-3p能够通过抑制ATG7蛋白质翻译抑制心脏自噬过程,对预防心肌梗死具有重要作用。而另一种叫做自噬促进因子(APF)的长非编码RNA能够直接与miR-188-3p结合抑制其活性,促进ATG7的蛋白质翻译,进而影响自噬过程。总的来说,APF lncRNA会通过调节miR-188-3p,影响ATG7表达、自噬介导的细胞死亡和心肌梗死。
 
这一研究揭示了由APF、miR-188-3p和ATG7组成的调节心脏自噬过程的新模式。通过调节他们的表达水平或可作为诊断治疗心肌梗死和心力衰竭的新工具和新策略。(文章详见 --Nat Commun:华人研究,自噬调节心肌梗死新模式

【4】Oncotarget:PTPRO介导的自噬可以阻止脂肪肝和肝细胞癌发生

以往研究表明细胞自噬在非酒精性脂肪肝(NASH)和肝细胞癌(HCC)的进展中起非常重要的作用。蛋白酪氨酸磷酸酶受体O (PTPRO)是最近发现的肿瘤抑制因子,但是关于它在NASH的研究很少。近来有研究,证明PTPRO介导的细胞自噬与胰岛素抵抗、脂代谢、肝癌发生相关。

研究者选取同源的野生型小鼠(对照组)和ptpro−/−小鼠(试验组)作为实验对象,首先使用二乙基亚硝胺造NASH小鼠模型,然后分别给予两组小鼠高脂饮食16周。结果显示,与野生型小鼠相比,ptpro−/−小鼠出现了严重的肝损伤、胰岛素抵抗、肝脂肪变性及自噬缺陷。同时,PTPRO基因敲出也促进了脂质生成目标基因的表达,减少了β氧化途径相关基因的活性。此外,发现ptpro−/−小鼠中,AKT的激活增加,胞浆中p53积聚增多,这两种变化一起抑制细胞自噬。有趣地是,由于PTPRO基因敲出,与AKT激活相关的高胰岛素血症在高脂饮食的小鼠中进一步加重了。AKT的激活诱导MDMX/MDM2杂合物的稳定性,从而促进p53在胞浆中积聚。抑制AKT可以修复自噬和肝细胞中p53的积聚,这表明AKT作用于p53的上游基因。由于ptpro−/− 小鼠存在高胰岛素血症和自噬缺陷,高脂饮食可能加重其肝脂肪变性。重要的是,脂肪肝的肝细胞胞浆中PTPRO的表达明显减少与p53积聚增加有关。

最后,研究者认为其之前的研究已经证明与癌旁组织相比,肝细胞癌中PTPRO 的水平显著降低了,而小鼠实验进一步证明,与正常脂质饮食相比,高脂饮食抑制PTPRO的表达,PTPRO 可能通过PI3K/Akt/MDM4/MDM2/P53途径影响肝细胞自噬,进而调节胰岛素和脂质代谢。(文章详见--Oncotarget:PTPRO介导的自噬可以阻止脂肪肝和肝细胞癌发生

【5】Sci Rep:ZNF32通过mTOR通路抑制人乳腺癌细胞的自噬

自噬在机体的生理和病理过程中都能见到,其所起的作用是正面还是负面的尚未完全阐明,对肿瘤的研究尤其如此,值得关注。所以目前,关于自噬与各类肿瘤作用机制的研究非常热。

ZNF32是最近发现的锌指蛋白,它的功能尚不清楚。近来有研究第一次在人乳腺癌细胞(MCF-7)中证明,ZNF32对细胞自噬及自噬相关的细胞凋亡有影响,并且进一步阐明了其作用机制。研究者在提高或降低ZNF32水平的情况下,分别检测人乳腺癌细胞的自噬活性与LC3-II的表达,并使用抑制剂(雷帕霉素)或激活剂(表皮生长因子),来检测AKT/mTOR通路在ZNF32对人乳腺癌细胞自噬影响中的作用。使用H2O2与二酰胺诱导的人乳腺癌细胞凋亡模型来阐释ZNF32相关的自噬在人乳头状癌细胞凋亡中的作用。

结果表明,提高人乳腺癌细胞中ZNF32的表达,可以通过激活AKT/mTOR抑制自噬,进一步降低自噬相关的细胞凋亡,维持细胞的存活。相反地,通过转染SiRNA使ZNF32的表达受损,可以明显促进细胞自噬,进而增加自噬相关的细胞凋亡。此外,ZNF32对细胞自噬的影响在人乳腺癌移植瘤和乳腺癌患者中都可以检测到。

总之,ZNF32作为有效的自噬抑制剂,可以保护人乳腺癌细胞使其免于过多刺激诱导的细胞凋亡。(文章详见--Sci Rep:ZNF32通过mTOR通路抑制人乳腺癌细胞的自噬

【6】Cell Rep:阻断自噬 将癌细胞牢牢粘在原地

来自美国芝加哥大学的研究人员最近发现抑制细胞的自噬过程能够有效阻断肿瘤细胞迁移和肿瘤模型中的乳腺癌转移。这项研究表明自噬过程在肿瘤转移过程中发挥非常重要的作用,同时详细阐述了自噬促进细胞迁移的分子机制。相关研究结果发表在国际学术期刊Cell Reports上。

研究人员将进行了敲低处理的癌细胞注射到雌性小鼠的乳腺脂肪垫,这些癌细胞能够分裂增殖,形成原位乳腺肿瘤,但是无法转移到远端位点,比如肺,肝以及骨等器官。进一步观察发现这些癌细胞在形态学上与常见癌细胞有所不同,研究人员发现这些癌细胞的黏着斑数目更多,并且异常变大。黏着斑对于癌细胞的迁移非常重要,类似于坦克的履带,而细胞自噬过程则负责细胞后部黏着斑的分解。
 
研究人员发现如果自噬受到抑制,这些迁移性肿瘤细胞无法移动,而黏着斑由于无法得到分解,就会变得越来越大,将细胞固定在一个位置。随后,研究人员又对自噬与黏着斑分解的分子机制进行了深入探讨。
 
目前临床上有一些能够阻断自噬过程的药物,主要用于疟疾的预防和治疗,同时也在延缓肿瘤生长方面进行临床检测。如果最终结果能够证明这些药物也可以有效延缓肿瘤生长,将为肿瘤治疗带来新的选择。(文章详见--Cell Rep:阻断自噬 将癌细胞牢牢粘在原地

【7】Cell:范可尼贫血基因也在自噬和免疫中发挥功能

在一项新的研究中,来自美国德州大学西南医学中心(UTMC)、印第安纳大学医学院和三家欧洲科研机构的研究人员鉴定出范可尼贫血(Fanconi anemia, FA)途径中的基因的重要新功能,这一发现可能对开发用于治疗这种疾病和一些癌症的新疗法产生影响。相关研究结果于2016年4月28日在线发表在Cell期刊上,论文标题为“Fanconi Anemia Proteins Function in Mitophagy and Immunity”。

论文第一作者、UTMC自噬研究中心内科讲师Rhea Sumpter博士说,FA途径中的基因突变也能够在未患上这种疾病的癌症患者中发现到。这些突变包括FANCS(也被称作BRCA1)基因突变和FANCD1(也被称作BRCA2)基因突变,这些突变不论一个人是否患上FA,都极大地增加这些人患上家族性乳腺癌和卵巢癌的风险。

在这项研究中,研究人员发现FA基因是选择性自噬所必需的。特别地,人FANCC基因在两种类型的选择性自噬中发挥着关键性作用:移除细胞内的病毒(即病毒自噬, virophagy)和移除受损的被称作线粒体的细胞组分(mitophagy, 线粒体自噬)。这项针对小鼠的新研究证实很多FA途径蛋白是线粒体自噬所必需的。(文章详见--Cell:范可尼贫血基因也在自噬和免疫中发挥功能

【8】Nature:自噬能通过降解核纤层防止肿瘤的发生

《自然》(Nature)杂志上的一项研究,第一次证实在哺乳动物中自噬消化了细胞核物质。资深作者、细胞与发育生物学、遗传学和生物学系教授Shelley Berger博士说:“我们发现,在哺乳动物中自噬分子机器引导降解了核纤层 (nuclear lamina)元件。”

核纤层是紧贴于核膜内侧的一个蛋白纤维网络。它是细胞核中一个至关重要的网络,为细胞核提供了机械支持,也通过使得一些基因组区域更容易或不容易转录为信使RNA而调控了基因表达。

早期的一些研究在细胞核中检测出了一个叫做LC3的关键蛋白,在这一复杂机器自噬的一边。一个被认为在细胞质中发挥功能的自噬蛋白定位在了细胞核中,这提出了一个问题:为什么LC3起初会在细胞核中?
第一作者、博士后研究人员Zhixun Dou是在自噬方面有经验的一位研究者,他带着这一问题去到了Berger实验室。同时,论文的合著者、来自格拉斯哥大学的Peter Adams发布了以往一项有关核纤层瓦解的研究,在核纤层中他观察到核被膜一个奇怪的突出物(圆泡)进入到了细胞质中,这些大泡中包含有DNA、核纤层蛋白和染色质。这引导了Berger和Adams实验室合作来阐明正在发生的事情。

利用先进的生化和测序方法,Zhixun Dou发现核纤层的一个关键组件laminB1及LC3在染色质上的相同位置相互接触。事实上,研究人员意外地发现,LC3和laminB1在物理上相互结合,LC3直接与lamin B1互作,结合到了染色质上的LAD(Lamina associated domains)区域。(文章详见--Nature:自噬能通过降解核纤层防止肿瘤的发生

【9】J Pineal Res:神经酰胺可以调节褪黑素诱导的肝癌细胞自噬和凋亡

近来有研究评价了褪黑素在细胞自噬和神经酰胺代谢中的影响,及神经酰胺代谢在褪黑素诱导的肝癌细胞凋亡中的作用。研究结果发现,褪黑素(2 mM)可以通过氨基末端激酶(JNK)的磷酸化,瞬时诱导HepG2细胞发生自噬,表现为Beclin1的表达增加,p62降解和LC3II与LAMP2的共表达,提示细胞活性降低。此外,ATG5-基因沉默技术会增加HepG2细胞对褪黑素诱导的细胞凋亡的敏感性,这提示自噬在细胞坏死中起双重作用。

褪黑素可以通过从头合成和刺激酸性鞘磷脂酶(ASMase)两种途径提高神经酰胺水平。

另外,研究者发现,使用多球壳菌素抑制丝氨酸棕榈酰转移酶(SPT),可以阻止褪黑素诱导的细胞自噬,而使用丙咪嗪抑制ASMase,会损害细胞的自噬过程。但是,抑制ASMase在部分程度上可以阻止HepG2细胞免于褪黑素的损害,而抑制SPT,却可以显著地提高细胞的死亡率。

这些研究结果提示,SPT介导的神经酰胺的生成和自噬在抵抗褪黑素诱导的细胞凋亡中,存在交叉影响,同时,特定的ASMase诱导的神经酰胺的生成参与褪黑素介导的细胞死亡。因此,双重的阻断SPT酶活性和细胞自噬,对褪黑素诱导的肝癌细胞的凋亡,起非常重要的作用。最后,研究者认为神经酰胺代谢可以调节褪黑素诱导的肝癌细胞的自噬和凋亡,抑制自噬可以提高褪黑素在肝癌治疗中的作用。(文章详见--J Pineal Res:神经酰胺可以调节褪黑素诱导的肝癌细胞自噬和凋亡

【10】Autophagy:组蛋白脱乙酰化酶抑制剂可通过FOXO1依赖的途径诱导自噬

自噬是细胞在饥饿、低氧及其他应激状态下,为维持细胞内代谢稳态,而进行的一种分解代谢过程。研究发现,组蛋白脱乙酰化酶抑制剂(HDACIs),可通过抑制雷帕霉素(MTOR)途径诱导细胞自噬。FOXO1,是受蛋白激酶B(AKT)调节的转录因子,在诱导自噬过程中非常重要的作用。

但是,目前关于FOXO1在HDACIs诱导的自噬过程中所起的作用尚无报道。近来,有研究首次分别在mRNA和蛋白水平,证明了HDACIs可以增加FOXO1的表达。同时,还发现HDACIs可以通过增加FOXO1的核聚集和提高FOXO1的转录活性。此外,通过siRNA敲除技术或者特殊的化学抑制剂,可抑制FOXO1的功能,从而显著的抑制HDACIs诱导的细胞自噬。研究者还发现,FOXO1介导的自噬是通过激活FOXO1的转录获得的,最终使诱导细胞自噬表现出双重的效应:1)提高自噬相关基因(ATG)的表达;2)通过SESN3 (sestrin 3)基因的转录抑制MTOR信号途径。最终,研究者发现抑制自噬可以显著提高HDACIs介导的细胞死亡,这提示自噬是有助于细胞存活的重要机制。
    
综上所述,研究者认为,在HDACIs介导的人类肿瘤细胞的自噬中,FOXO1其非常重要的作用,将HDACIs与自噬抑制剂结合应用,有望成为新型的抗肿瘤治疗策略。(文章详见--Autophagy:组蛋白脱乙酰化酶抑制剂可通过FOXO1依赖的途径诱导自噬

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-12-31 1e19f4d1m16(暂无匿称)

    受益匪浅学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-11-10 studylzc

    很强大

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-05 txqjm

    受益匪浅,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-05 xxxx1054
  5. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 童小孩

    希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 明月清辉

    谢谢分享,厉害。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 doctorJiangchao

    继续关注

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 doctorJiangchao

    继续学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=167064, encodeId=246616e0647a, content=受益匪浅学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de0e1989352, createdName=1e19f4d1m16(暂无匿称), createdTime=Sat Dec 31 14:51:01 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154888, encodeId=9179154888ac, content=很强大, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Thu Nov 10 21:53:35 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140474, encodeId=082c1404e4aa, content=受益匪浅,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 05 16:56:16 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548907, encodeId=65d9154890eff, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299318, encodeId=21a412993184b, content=<a href='/topic/show?id=1dd5e8010f5' target=_blank style='color:#2F92EE;'>#细胞自噬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78010, encryptionId=1dd5e8010f5, topicName=细胞自噬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Wed Oct 05 14:42:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=140094, encodeId=c54014009426, content=希望自噬抑制剂可以成为新一代,里程碑式的抗肿瘤药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Tue Oct 04 19:09:47 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139932, encodeId=d9fe139932e3, content=谢谢分享,厉害。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Tue Oct 04 13:48:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139922, encodeId=10fa13992279, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:21 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139921, encodeId=b64513992103, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Oct 04 13:03:15 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139795, encodeId=af1c139e954b, content=学习啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Tue Oct 04 09:06:36 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 医路开来

    学习啦,,,

    0

相关资讯

PNAS:肿瘤抑制基因ASPP2作为分子开关控制细胞自噬

身体有一个内置的自食称为自噬或系统控制细胞生或死的系统。自噬过程的失调与人类疾病包括神经变性和癌症的发展密切相关。 近日,在Proceedings of the National Academy of Sciences杂志上发表的一项研究,牛津路德维格癌症研究学会科学家发现了一个调节自噬的关键分子开关。他们还研究了自噬和衰老永久即细胞停止生长之间的联系。 研究人员发现一种肿瘤抑制基因A

Autophagy:中科院科学家阐述NAC复合体在细胞自噬中的功能

2014年10月, 中科院生物物理所张宏研究组在国际著名期刊Autophagy上发表题为“The nascent polypeptide-associated complex is essential for autophagic flux”的文章报告了其最新研究成果。研究人员采用RNAi的方法使相应基因在线虫发育特定阶段失活。利用这种手段,张宏等人进行全基因组RNAi筛选,通过分析线虫肠道细胞中

Nat Commun:华人研究,自噬调节心肌梗死新模式

近日,来自青岛大学的研究人员在国际学术期刊nature communication在线发表了他们的最新研究进展,他们发现一种叫做自噬促进因子(APF)的长非编码RNA能够通过靶向miR-188-3p和ATG7调节自噬,在心肌梗死诊断和治疗方面具有一定意义。   细胞自噬是对环境应激的一种进化保守应答过程。在自噬发生过程中,细胞内冗余成分如异常聚集的蛋白质和损伤的细胞器会被自噬小泡

Sci Rep:ZNF32通过mTOR通路抑制人乳腺癌细胞的自噬

自噬(autophagy)是由 Ashford 和 Porter 在 1962 年发现细胞内有“自己吃自己”的现象后提出的,是指从粗面内质网的无核糖体附着区脱落的双层膜包裹部分胞质和细胞内需降解的细胞器、蛋白质等成分形成自噬体(autophagosome),并与溶酶体融合形成自噬溶酶体,降解其所包裹的内容物,以实现细胞本身的代谢需要和某些细胞器的更新。自噬在机体的生理和病理过程中都能见到,其所起的